Publications by authors named "H Mogun"
Article Synopsis
- The study focuses on understanding the risk of spontaneous abortion (SAB) and termination using Medicaid healthcare data, requiring accurate algorithms to estimate gestational age (GA).
- Researchers created a hierarchical algorithm to classify pregnancy outcomes and developed three approaches to estimate GA: using median GA, random distribution, and regression models.
- The best-performing approach utilized random forest models and achieved 58.0% accuracy for SAB and 66.3% for terminations within 2 weeks of the gold standard, highlighting the feasibility of studying these outcomes despite some misclassification issues.
Importance: Buprenorphine combined with naloxone is commonly used to treat opioid use disorders outside of pregnancy. In pregnancy, buprenorphine alone is generally recommended because of limited perinatal safety data on the combination product.
Objective: To compare perinatal outcomes following prenatal exposure to buprenorphine with naloxone vs buprenorphine alone.
Objective: We emulated a modified randomized trial (Metformin in Women With Type 2 Diabetes in Pregnancy [MiTy]) to compare the perinatal outcomes in women continuing versus discontinuing metformin during pregnancy among those with type 2 diabetes treated with metformin plus insulin before pregnancy.
Research Design And Methods: This study used two health care claims databases (U.S.
Background: Maternal use of valproate during pregnancy has been associated with an increased risk of neurodevelopmental disorders in children. Although most studies of other antiseizure medications have not shown increased risks of these disorders, there are limited and conflicting data regarding the risk of autism spectrum disorder associated with maternal topiramate use.
Methods: We identified a population-based cohort of pregnant women and their children within two health care utilization databases in the United States, with data from 2000 through 2020.
Importance: Use of medications for attention-deficit/hyperactivity disorder (ADHD) during pregnancy is increasing in the US. Whether exposure to these medications in utero impacts the risk of neurodevelopmental disorders in children is uncertain.
Objective: To evaluate the association of childhood neurodevelopmental disorders with in utero exposure to stimulant medications for ADHD.